Login / Signup

Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile.

Jacob NewJason ChamLana SmithLeah PuglisiTridu HuynhSunil KurianSamantha BagsicRussel FieldingLee HongPriya ReddyKi Suk EumAllison MartinBethany BarrickChristopher MarshMichael QuigleyLaura J NicholsonAmitabh C Pandey
Published in: Journal for immunotherapy of cancer (2024)
Antineoplastic and immunomodulating medications associate with an elevated risk of postimmunization SARS-CoV-2 infection in a drug-specific manner. This comprehensive, unbiased analysis of all WHO ATC classified antineoplastic and immunomodulating medications identifies medications associated with greatest risk. These findings are crucial in guiding and refining vaccination strategies for patients prescribed these treatments, ensuring optimized protection for this susceptible population in future COVID-19 variant surges and potentially for other RNA immunization targets.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • genome wide
  • emergency department